The injection known as Gohibic targets a part of the immune system that is thought to play a
role in the inflammation that leads to COVID-19 disease progression.
New Delhi: The U.S. Food and Drug Administration (FDA) on Tuesday granted emergency-use authorization to Inflarx NV’s monoclonal antibody for the treatment of hospitalized COVID patients when initiated within 48 hours of receiving artificial life support.
